- The US Food and Drug Administration (FDA) has granted approval revance therapeutics‘ RVNC Lead asset DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the temporary improvement of moderate to severe forehead (glabellar) lines in adults. Revance shares traded up 22.39 percent, ranging from $22.02 to $25.47 on daily volume of 8.73 million shares versus an average three-month volume of 729.3 thousand shares that ended the regular trading session $25.30 finished.
- Silent Therapeutics SLN announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its lead candidate SLN124 for the treatment of polycythemia vera (PV). Silence Therapeutics shares traded up 15.55 percent in a range of $11.23 to $13.3 on daily volume of 38.34k shares and closed the regular trading session at $11.40.
- The Medical Healthcare & Products Regulatory Agency (MHRA) has granted Marketing Authorization Authorization (MAA) and Orphan Disease Designation (ODD) for amryte‘s AMYT Lead candidate Filsuvez for the treatment of partial wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients aged 6 months and older in the United Kingdom (GB). Amryt shares traded up 3.79 percent in a range of $7.66 to $7.95 on daily volume of 26.2 thousand shares and closed the regular trading session at $7.84.
- Alnylam ALNY announced positive results from the Phase 3 APOLLO-B study of patisiran, an investigational RNAi therapeutic for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy. The results were announced today in a late breaker session at the 18thth International Symposium on Amyloidosis (ISA). Alnylam shares traded up 8.76 percent, ranging from $203.86 to $227.16 on daily volume of 2 million shares versus an average three month volume of 1 million shares, ending the regular trading session at 226.30 $.
- Axsome Therapeutics AXSM enrolled the first patient in the ADVANCE-2 study of AXS-05,…
[ad_2]
Source story
